This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Novus Biologicals
other brands :
IMGENEX
product type :
antibody
product name :
IL-20 R beta / FNDC6 Antibody (20RNTC)
catalog :
NBP2-00466
quantity :
100 ug (also 25 ug)
price :
329 USD
clonality :
monoclonal
host :
rat
conjugate :
nonconjugated
clone name :
20RNTC
reactivity :
human, mouse
application :
immunocytochemistry, flow cytometry
product information
SKU :
NBP2-00466-100ug
product name :
IL-20 R beta / FNDC6 Antibody (20RNTC)
unit size :
100 ug (also 25 ug)
Description :
The IL-20 R beta/FNDC6 Antibody (20RNTC) from Novus is a rat monoclonal antibody to IL-20 R beta/FNDC6. This antibody reacts with human, mouse. The IL-20 R beta/FNDC6 Antibody (20RNTC) has been validated for the following applications: Flow Cytometry, Immunocytochemistry/Immunofluorescence.
target :
IL-20 R beta / FNDC6
category :
Primary Antibodies
buffer :
PBS (pH 7.2)
clonality :
Monoclonal
clone :
20RNTC
concentration :
0.5 mg/ml
conjugate :
Unconjugated
host :
Rat
immunogen :
The immunogen for this antibody is FNDC6 (IL-20R2).
isotype :
IgG2a Kappa
purity :
Protein A or G purified
species :
Human, Mouse
gene symbol :
IL20RB
catalog number base :
NBP2-00466
applications :
Flow Cytometry, Immunocytochemistry/Immunofluorescence
2020 Proposedprice USD :
329 USD
alt names :
FNDC6, DIRS1, IL-20R2, IL20RB interleukin 20 receptor beta, MGC34923
storage :
Store at 4C. Do not freeze.
company information

Novus Biologicals
8100 Southpark Way, A-8
Littleton, CO 80120
Littleton, CO 80120
novus@novusbio.com
https://www.novusbio.com3037301950
headquarters: USA
Novus Biologicals licenses, manufactures, and markets antibodies to over 20,000 unique targets to support a wide array of research areas. Novus is built on honesty, collaboration and strong relationships and continues to provide quality tools that accelerate research. Every product is backed by our 100% guarantee.
questions and comments